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Abstract 
Background: Extended spectrum beta lactamase (ESBL)-producing extraintestinal pathogenic Escherichia coli infec-
tions are of global interest because of their clinical and economic impact. The ESBL resistance genes disseminate 
through plasmids, and are found in successful global lineages such as ST131 and ST648. The carriage of plasmids has 
been suggested to result in a fitness burden, but recently it was shown that ESBL-plasmids enhanced virulence in 
pandemic ST131 and ST648 lineages without affecting their fitness. Herein, we investigated the influence of ESBL-
plasmids on bacterial competition and serum resistance, both of which are essential characteristics of ExPEC during 
infections.
Methods: Triplets of ESBL-plasmid-carrying wildtype (WT), plasmid-cured variant (PCV) and transformant (T) of five 
ExPEC strains of ST131 and ST648 were used for bacterial competition experiments with colicin-producing com-
mensal E. coli, competitive adhesion experiments and serum survival. In addition, resilience after SDS, acid, osmotic 
challenges and RNA sequence data were analyzed.
Results: In all five strains tested, ESBL-plasmid carriage did not negatively influence E. coli fitness in direct bacterial 
competition with commensal E. coli in vitro. That is, WTs did not show any disadvantages when compared to their iso-
genic plasmid-free PCV. For one strain we even found the opposite as PCV17433 was out-competed by a commensal 
strain, which suggests an even protective role of the ESBL-plasmid carried by the WT17433. Similarly, in the serum-
resistance experiments, the PCVs of two strains (PCV17433 and PCV17887) were more sensitive to serum, unlike WTs 
and Ts. The observed inter-strain differences could be explained by the different genetic content of plasmids carried 
in those strains.
Conclusions: Overall, we found no compelling evidence for an increased burden resulting from the carriage of 
ESBL-plasmids in the absence of antimicrobial selection pressure in the strains of pandemic ST131 and ST648; rather, 
the possession of certain ESBL-plasmids was beneficial for some strains in regarding competition fitness and serum 
survival.
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Background
Escherichia coli (E. coli) are among the most common 
pathogens of extra-intestinal (ExPEC) and intestinal 
infections (InPEC) in humans and animals [1, 2]. ExPEC 
cause urinary tract, bloodstream, skin, and soft tis-
sue infections as well as meningitis in humans and are 
causative agents for colisepticemia and other infections 
in poultry [1, 3, 4]. Treatment of ExPEC with antimicro-
bial agents results in an significant economic burden to 
healthcare facilities and in the poultry industry [5]. In 
recent years, an increase in resistance towards antimi-
crobials, including third generation cephalosporins, due 
to the production of extended-spectrum beta-lactamases 
(ESBL), has reduced treatment possibilities [6]. Dissemi-
nation of ESBL occurs not only through resistance plas-
mids, in addition certain clones referred to as “high risk 
clones” (HRC) such as ST131 and ST648 are also respon-
sible for the spread across different niches [7, 8]. ST131 
is the predominant clone isolated from E. coli infections 
reported worldwide, whereas ST648 is an emerging high 
risk clone reported in recent years from various habitats 
[3, 9–12]. For both clones, recent advances in their detec-
tion will likely further increase their identification as con-
tributors to E. coli infections [13, 14].
Although ST131 (phylogroup B2) and ST648 (phylo-
group D) differ in their phylogenetic background, both 
lineages show similar epidemiological success, and dis-
seminate resistance traits equally in different populations 
[11, 15]. Both lineages also often host large ESBL-plas-
mids carrying CTX-M enzymes, which have also been 
found integrated into the chromosome [16, 17]. ESBL-
plasmids have been reported to confer fitness costs for 
the host strain [18], but in addition to resistance factors, 
they also carry a large number of non-resistance genes. 
These “cargo” genes encode for variety of uncharacter-
ized, hypothetical proteins, and their possible impact 
on fitness are yet to be explored [19]. Recently, we dem-
onstrated that ESBL-plasmids do not reduce fitness in 
strains of these pandemic sequence types ST131 and 
ST648, but rather contributed to virulence in terms of 
biofilm formation in some strains through interactions 
between plasmid and host chromosomally-encoded fac-
tors [20]. This observation likely contributes to the suc-
cess of certain HRC worldwide, including environments 
with low antimicrobial selection pressures.
The majority of ESBL-producing E. coli are ExPEC, 
capable of causing severe bloodstream infections. Thus, 
serum survival is an important virulence trait in those 
pathogens. In this study, we investigated whether E. coli 
wildtype isolates of two HRC clones, ST131 and ST648, 
which harbor ESBL-plasmids, demonstrate better serum 
survival when compared to their isogenic, ESBL-plasmid-
free variant (PCV). As the reservoir of ExPEC is mainly 
the gut of humans and animals, intestinal epithelial 
adhesion is a preliminary step to colonization and sys-
temic infection in competition with other bacteria. We 
performed competition assays with commensal, colicin-
producing ST10 E. coli strains, alone and in combination 
with cell culture adhesion assays, to determine the overall 
competition fitness and adhesion with regard to the pres-
ence of the ESBL-plasmids.
Methods
Bacterial strains
Five wildtype ESBL-producing E. coli strains of two 
STs (ST131: IMT17433, IMT27685, IMT19205, ST648: 
IMT17887, IMT16316), their ESBL-plasmid-cured vari-
ants (PCV) and transformants (T) with a reintroduced 
ESBL-plasmid were analyzed in this study [21]. The iso-
lates have been characterized in a previous publication 
[20, 21]. The details of plasmids and their properties 
are summarized in Additional file  1: Table  S1. Strains 
and plasmids were chosen based on their original host, 
type of disease, size of the plasmid, CTX-M variant and 
inc/rep types, resulting in a broad spectrum of differ-
ent combinations of plasmids with the bacterial chro-
mosome. Two commensal strains of ST10 originally 
isolated from human gut [IMT13353 (colicin V, colicin 
M) and IMT13858 (colicin V, colicin E1), both resistant 
to chromosomally-encoded chloramphenicol] were used 
as colicin-producing commensal competitor strains. 
PCV19205 was not used for competition and competitive 
adhesion experiments as it was sensitive to the antibiotic 
enrofloxacin.
Colicin extraction and activity assay
Colicin extraction was prepared as described earlier with 
modifications [22]. To test colicin activity, 5 ml of auto-
claved 0.7% agar (close to solidifying temperature) was 
mixed with 60  μl of overnight-grown colicin-sensitive 
strains (E. coli BL-21-DE3 and MG1655) and poured 
onto LB agar plates.  5  μl of the extracted sample were 
added on top and incubated overnight at 37 °C. Zones of 
inhibited growth of the colicin-sensitive strains indicated 
colicin activity.
Phenotypic microarray (PM)
The metabolic capability of the two colicin-producing 
ST10 competitor strains was determined using the 
BioLog Omnilog system and growth curves as described 
previously [20]. Six plates, PM1 to PM4, PM13 and PM14 
(http://www.biolo g.com/produ cts-stati c/pheno type_
micro bial_cells _micro Plate _panel s_and_media .php) 
were used. PM1 to PM4 contain carbon, nitrogen, phos-
phorus and sulphur sources, PM13 and 14 contain anti-
microbials and other chemical compounds. The plates 
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were inoculated following the manufacturer’s instruc-
tions and grown for 48  h at 37  °C. The experiment was 
performed using three biological replicates. Data were 
analyzed using the statistics program R and heat maps 
were generated taking the area under curve (AUC) value 
for each well, normalized by the negative control wells 
[20, 23].
Competition assay
Single competition assays between colicin-producing 
E. coli ST10 and the different variants of the ESBL-
strains (WT, PCV or T) were performed. Experiments 
were repeated three times. Briefly, overnight cultures 
were grown to an  OD600 = 1. One millilitre of each WT, 
PCV or T and the colicin-producing strain were added 
to 98 ml of LB medium and grown at 37 °C. At 60 min. 
intervals, 1 ml of culture was collected in duplicate. Fol-
lowing serial dilution, 100 μl of three different dilutions 
were used for differential plating. We used LB plates con-
taining 4 µg/ml enrofloxacin (WT, PCV and T: enrofloxa-
cin resistant and chloramphenicol sensitive), 32  μg/ml 
chloramphenicol (colicin-producing E. coli ST10: chlo-
ramphenicol resistant and enrofloxacin sensitive) and 
both (any possible transformation). Growth was deter-
mined by colony forming units (CFU) and graphs were 
plotted using GraphPad prism 5.01.
Competitive adhesion experiments
Competitive adhesion experiments between colicin-pro-
ducing E. coli ST10 and ESBL-triplets (WT, PCV and T) 
on porcine small intestinal (IPEC-J2) cell lines were per-
formed as described elsewhere with modifications for 
differential plating [24]. The experiments were performed 
for each combination using three biological replicates 
and three technical replicates.
Serum resistance experiments
Serum experiments were performed in human and 
chicken serum (Pan biotech, Germany) as described pre-
viously [24]. 5 μl of overnight grown culture were inoc-
ulated in 495  μl fresh LB medium and grown for 1.5  h. 
Bacteria were centrifuged at 7500×g for 3 min and resus-
pended in 1 ml of sterile 1X PBS. Thirty microliters were 
added in triplicates to 96-well microtiter plates contain-
ing 270  μl of 50% serum. Thirty microliters of sample 
were collected from each well, serially diluted and plated 
on LB plates (0 h count). The microtiter plates were incu-
bated for 4  h at 37  °C. Following incubation, 30  μl of 
culture was plated as previously described (4  h count). 
Growth in serum was obtained by determining differ-
ences in the CFU after 4 h of incubation to that of 0 h. 
This experiment was performed with three technical and 
three biological replicates.
RNA sequencing
Comparative RNA sequencing data of the WT, PCV 
and T of IMT17433 from our previous study was used 
to detect up- or down-regulated genes, which had been 
described to be involved in bacterial competition and 
serum resistance. Details on the RNA isolation procedure 
and gene regulation data analysis can be found in the 
original publication [20].
Survival in SDS and under acidic and osmotic stress
Two strains triplets showing differences in bacterial com-
petition and serum survival (WT/PCV/T17433, WT/
PCV/T17887) and one control (WT/PCV/T16316) were 
used to analyze survival in 2% SDS, pH 3.8 and 5 M NaCl. 
The experiments were performed according to Wang 
[25].
Statistical analysis
All statistical tests were performed using GraphPad 
Prism 5.01. Mann–Whitney U test was performed to cal-
culate the p values for serum resistance and competitive 
adhesion experiments and values < 0.05 was considered 
as significant.
Results
Commensal strains produce colicin
Colicin production was detected as clear zones around 
the spots plated with colicin extract onto colicin-sensitive 
strains. Colicin extracts of both the competitor strains 
IMT13353 and IMT13858 showed clear zones on colicin-
sensitive strains E. coli BL21 (λDE3) and MG1655, indi-
cating the colicin production by these strains. Both the 
competitor strains IMT13353 and IMT13858 exhibited 
resistance to chloramphenicol which was chromosom-
ally-encoded and used as selection marker for further 
experiments.
Metabolic profiles among the competitor and wild type 
strains are comparable
To determine whether differences in metabolic activi-
ties might confer competitive disadvantages among the 
strains, we performed phenotypic microarray profiling 
using Omnilog plates containing different metabolites. 
We observed no significant differences in the metabolic 
profiles between the competitor strains IMT13353 and 
IMT13858, or any of the five wildtype ESBL strains for 
all four assays for carbon, nitrogen, phosphorous and 
sulphur sources (Additional file  1: Figure S1A–D), con-
sistent with our previous study [20]. Thus, metabolic dif-
ferences would not appear to contribute a significant role 
in possible phenotypes among competitor and wildtype 
strains.
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Competition reveals PCV17433 exceptional behavior 
against one ST10 strain
Both the ST10 colicin-producing commensal strains 
showed similar growth curves. In competitive growth 
assays, all three variants of the four strains IMT16316, 
IMT17433, IMT17887 and IMT27685 showed no differ-
ences in growth in the presence of the competitor strain 
IMT13353, and showed similar CFU counts for five hours 
of competition (Additional file  1: Figure S2A–F). How-
ever, in competitive growth assays with strain IMT13858, 
strain PCV17433 showed reduced growth, whereas for 
both the wildtype IMT17433 and plasmid-complemented 
strain, no differences were observed (Fig. 1). This excep-
tional behavior of PCV17433 suggested a possible role 
for the ESBL-plasmid in IMT17433 in protection against 
the colicin produced by IMT13858.
PCV17433 (ST131) and PCV17887 (ST648) adhere 
significantly less in competitive adhesion with commensal 
strains
ExPEC strains are known to adhere to variety of epithelial 
cells. We therefore also performed competitive adhesion 
assays with both commensal ST10 strains against the four 
strains of HRC (ST131 and ST648) in the porcine, intes-
tinal epithelial IPEC-J2 cell line. Strain PCV17433 was 
found to adhere significantly less than its variants in the 
adhesion competition assays. Likewise, strain PCV17887 
showed a similar behavior against both the competi-
tor strains IMT13353 and IMT13858 (Fig.  2a, b). These 
results suggested a role for the respective ESBL-plasmids 
in both adhesion in a competitive environment and pro-
tective effects against colicin-producing commensal 
strains.
PCV17433 and PCV17887 are sensitive to different serum
Resistance to serum during infection is an important 
virulence property of ExPEC strains [26]. We there-
fore determined the resistance against both human and 
chicken serum. Consistent with prior observations, we 
found the plasmid-cured strain PCV17433 to be signifi-
cantly more sensitive to both human as well as chicken 
serum (Fig.  3a, b). Interestingly, strain PCV17887 was 
sensitive to human serum but not to chicken serum. All 
five wildtype strains showed resistance to sera, and the 
plasmid-complemented (T) variants regained wildtype 
resistance, with few exceptions.
Genes belonging to serum resistome are upregulated 
in WT strains
Resistance towards serum is complex and involves 
many different processes. The serum resistome has been 
described to comprise 56 essential genes or factors in a 
Fig. 1 a Growth curve of both competitors, b growth curve of triplet of IMT17433 without competition and competition assay of the triplet of 
IMT17433 with competitor strain c IMT13353 and d IMT13858. Growth is measured in terms of colony forming units for a period of five hours
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ST131 strain (EC958) [26]. Several of these factors, nha, 
dnaJ, acrA and pgm, were found to be upregulated by 
more than twofold in the wildtype strains of these same 
isolates in RNA seq data in our earlier study [20]. Fur-
thermore, ompA was upregulated more than 2.4-fold 
compared to the PCV variant of the wildtype strain. 
OmpA is involved in serum resistance and has been 
described previously in E. coli K-12 [27]. These results 
suggest the ESBL-plasmids influence serum resistance in 
some strains of pandemic ST131 and ST648 isolates.
PCV17433 and PCV17887 shows decreased survival 
in osmotic, salt and acid stress
Outer membrane proteins are additionally involved in a 
variety of functions related to stress in pathogenic organ-
isms. We therefore determined whether the PCV variants 
also demonstrated differences in growth during stress 
conditions such as high salt (NaCl), SDS, and acid stress. 
As shown in (Fig.  4a–c), PCV17433 and PCV17887 
both showed reduced survival compared to their WT 
and complemented (T) variant in all three stress condi-
tions. No such changes were observed in control strain 
IMT16316 and its variants.
Discussion
The emergence and dissemination of ESBL-producing E. 
coli are of global concern, as treatment opportunities are 
now restricted to the use of last resort antibiotics such as 
carbapenems [28]. This situation has become more pre-
carious, as an increase in carbapenem-resistant strains 
has been reported worldwide [28, 29]. Although the dis-
semination is largely driven by resistance plasmids, high 
Fig. 2 Competitive adhesion assay in IPEC-J2 cells with competitor strain a IMT13353 and b IMT13858. Growth is measured in terms of colony 
forming units. ns represents non significant p value while **p value ≤ 0.01 and ***p value ≤ 0.001
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risk clones such as ST131 or ST648 also play an impor-
tant role, as they represent successful lineages which 
dominate clinical cases across different host and sites [11, 
12].
A large number of hypothetical genes from these large 
plasmids remain unexplored, and their implications 
with regard to clinical or virulence attributes are still 
unknown. In a previous study we found that ESBL-plas-
mids enhance biofilm formation in ST131 and ST648 E. 
coli [20]. Here, we explored possible impact of different 
ESBL-plasmids on important virulence characteristics 
such as competition with commensal microorganisms, 
and serum-resistance. Five different strains harboring 
different plasmids (Additional file 1) were chosen based 
on their original host type, disease association, size of the 
plasmid, CTX-M variant and inc/rep types. We exam-
ined different combinations of plasmids with isolates of 
ST648 and ST131 to obtain an initial impression as to 
which virulence traits might be affected by ESBL-plasmid 
carriage. The differences in genetic content of the plas-
mids (Additional file  1: Figure S3) may harbor clues to 
explain the differences in the beneficial effects of plasmid 
carriage.
The onset of an infection by a pathogen begins with 
competition against endogenous microorganisms. Com-
mensal strains are believed to act as protective micro-
biota which compete for both metabolic as well as niche 
space in the host [30]. We observed that all the strains 
were equally competitive, and had similar growth kinet-
ics against both the commensal colicin-producing 
strains, except for the isolate PCV17433, which was out-
competed in competition against IMT13858 (Fig.  1 and 
Additional file  1: Figure S2A–F). This observation sug-
gests a protective role for the ESBL plasmid harbored 
by IMT17433 against colicin or competition, as both the 
wild type and re-transformed (T) variant showed similar 
Fig. 3 Serum bactericidal activity of triplets of all five strains in 50% a human serum, b chicken serum. IMT209 is used as negative control while 
IMT5155 as positive control for the assay. p values are represented by asterisk wherever significant as; *p value ≤ 0.05, **p value ≤ 0.01 and ***p 
value ≤ 0.001
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growth. As both the competitors and wild type strains 
had similar metabolic capabilities, and all the variants 
showed similar capabilities to utilize different meta-
bolic substrates, a role for metabolic competition seems 
unlikely. A similar observation was seen for competitive 
adhesion against both competitors in a porcine intestinal 
cell line. However, the PCV variant of IMT17887 belong-
ing to ST648 showed lower colony counts in adhesion 
competition assays (Fig.  2), suggesting possible roles of 
ESBL-plasmids in competition or colicin protection.
Serum resistance is an important virulence characteris-
tic of ExPEC. Serum resistance is mediated by large num-
ber of factors including the outer membrane proteins 
and plasmid associated factors [31, 32]. Phan et  al. [26] 
demonstrated 56 genes which were essential for serum 
survival in EC958 (ST131) strain defining the serum 
Fig. 4 Growth of triplets in stress conditions a 2 M SDS, b 5 M NaCl and c Acetic acid. Survival in SDS and NaCl is represented in terms of percent 
survival while in acetic acid it is represented in terms of colony forming units (CFU)
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resistome in ST131 dominant lineage. We observed that 
both PCV variants of IMT17433 and IMT17887 were 
sensitive to human serum, while PCV17433 was addi-
tionally sensitive to chicken serum (Fig. 3). As the ESBL-
plasmid and sequence type vary between the two strains, 
and constituents of human and chicken serum are differ-
ent this suggest that the PCV17887 variant might harbor 
additional serum resistance determinants. Nevertheless, 
these results suggest the possible involvement of ESBL 
plasmids in serum resistance. Earlier reports had shown 
that the introduction of ESBL-plasmid in the J53 conju-
gative strain increased its serum resistance, and ESBL-
producing strains had higher serum resistance than non 
ESBL-producing strains [33, 34]. However, to our knowl-
edge, we have shown for the first time enhanced serum 
resistance by transfer of an ESBL-plasmid into an iso-
genic background of the pandemic sequence types ST131 
and ST648.
We observed the upregulation of factors like ompA, 
known to enhance serum resistance in K12 E. coli [27] 
and nha, dnaJ, acrA, which are the constituents of the 
serum resistome. Outer membrane proteins are one of 
the essential components, and are involved in many of 
the stress related defenses in pathogenic organisms. We 
observed that the PCV17443 and PCV17887 variants 
showed reduced viability and/growth in osmotic, salt, 
and acid stress. In none of the isolate variants did we 
observe an additional fitness cost due to plasmid carriage 
in isolates harboring an ESBL-plasmid. As the experi-
ments were performed with unique triplets of wild type, 
plasmid-cured (PCV) and complemented (T) strains, the 
observed differences in phenotypes appear to be solely 
dictated by in presence of the respective plasmids.
Conclusions
The inheritance of ESBL-plasmids in strains of the 
sequence types ST648 and ST131 does not lead to a gen-
eral fitness burden in bacterial competition or serum 
resistance assays. For certain combinations of ESBL-plas-
mids with different bacterial chromosomal backgrounds, 
we observed that plasmids could confer beneficial viru-
lence properties in some of strains of pandemic sequence 
types of ST131 and ST648.
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